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Dermal fibroblasts cultured 
from donors with type 2 diabetes 
mellitus retain an epigenetic 
memory associated with poor 
wound healing responses
Aaiad H. A. Al‑Rikabi1,3, Desmond J. Tobin2, Kirsten Riches‑Suman1 & M. Julie Thornton1*
The prevalence of Type 2 diabetes mellitus (T2DM) is escalating globally. Patients suffer from 
multiple complications including the development of chronic wounds that can lead to amputation. 
These wounds are characterised by an inflammatory environment including elevated tumour 
necrosis factor alpha (TNF‑α). Dermal fibroblasts (DF) are critical for effective wound healing, so we 
sought to establish whether there were any differences in DF cultured from T2DM donors or those 
without diabetes (ND‑DF). ND‑ and T2DM‑DF when cultured similarly in vitro secreted comparable 
concentrations of TNF‑α. Functionally, pre‑treatment with TNF‑α reduced the proliferation of ND‑DF 
and transiently altered ND‑DF morphology; however, T2DM‑DF were resistant to these TNF‑α induced 
changes. In contrast, TNF‑α inhibited ND‑ and T2DM‑DF migration and matrix metalloprotease 
expression to the same degree, although T2DM‑DF expressed significantly higher levels of tissue 
inhibitor of metalloproteases (TIMP)‑2. Finally, TNF‑α significantly increased the secretion of pro‑
inflammatory cytokines (including CCL2, CXCL1 and SERPINE1) in ND‑DF, whilst this effect in 
T2DM‑DF was blunted, presumably due to the tendency to higher baseline pro‑inflammatory cytokine 
expression observed in this cell type. Collectively, these data demonstrate that T2DM‑DF exhibit a 
selective loss of responsiveness to TNF‑α, particularly regarding proliferative and secretory functions. 
This highlights important phenotypic changes in T2DM‑DF that may explain the susceptibility to 
chronic wounds in these patients.
Patients with type 2 diabetes mellitus (T2DM) suffer from impaired wound healing with persistent inflamma-
tion, micro- and macro-circulatory dysfunction, hypoxia, and impaired neuropeptide signalling. This can result 
in a chronic, non-healing, diabetic foot ulcer, with significant risk of foot, or lower limb  amputation1. Typically, 
cutaneous wound healing follows three sequential, overlapping phases; an inflammatory phase, a prolifera-
tive phase and a remodelling  phase2. The inflammatory phase takes place early in the sequence, lasting only a 
few days, followed by progression to tissue regeneration and re-epithelialisation, granulation tissue formation, 
angiogenesis and tissue  remodelling3.
Dermal fibroblasts (DF) play a pivotal role during cutaneous wound healing; they proliferate and migrate 
into the wound bed to produce extracellular matrix (ECM) proteins that are essential for the generation of the 
granulation tissue and in providing a scaffold for the migration of inflammatory  cells2,4. During the inflammatory 
phase DF also secrete an array of cytokines, chemokines and growth factors that synchronise the migration of 
immune cells to the wound bed and control their retention and survival in damaged  tissue5,6. Hence, DF have a 
potential role in regulating the switch from acute inflammatory responses to chronic persistent  inflammation7.
Chronic, non-healing wounds associated with diabetes exhibit an interruption in the normal healing 
 process8,9. These wounds are characterised by a prolonged inflammatory phase, altered production of pro- and 
anti-inflammatory cytokines and impaired angiogenesis. DF exhibit diminished ECM synthesis and a decrease 
in their migratory and proliferative capacity. In addition, the migration and proliferation of keratinocytes is also 
decreased, which compromises the restoration of the epidermal  barrier10,11.
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The pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) plays a key role in controlling the 
inflammatory process during wound healing. However, continual, elevated levels of TNF-α can extend the 
inflammatory phase, which correlates with chronic, non-healing wounds, where there is no resolution of 
 inflammation12–14. Therefore, the effects of TNF-α during the wound healing process are both time and concen-
tration-dependent and TNF-α can initiate various effects on the DF. Lower concentrations of TNF-α promote 
remodelling/healing of injured tissue by stimulating inflammatory macrophages that secrete growth factors 
required to stimulate DF  proliferation15. However, high concentrations of TNF-α for extended periods actu-
ally induce DF apoptosis with a deleterious effect on wound  healing16. TNF-α inhibits their differentiation into 
myofibroblasts, which are important in the physical contraction of the  wound17. High levels of TNF-α also inhibit 
synthesis of key ECM proteins such as fibronectin and type I collagen. Therefore, excessive and extensive expo-
sure may contribute to chronic non-healing wounds prevalent in T2DM. Circulating plasma levels of TNF-α 
are typically around 10 pg/ml18 but in diabetic patients can be almost tenfold  higher19 and circulating TNF-α 
concentrations positively correlate with diabetes  duration20. In healthy skin tissue, concentrations of TNF-α are 
highly variable but typically in the order of 1.5 ng/ml21. However, TNF-α levels are three times higher in wound 
fluid from non-healing venous leg ulcers compared to healing  ulcers22, and wounds of diabetic mice have higher 
levels of TNF-α compared to their normoglycaemic  littermates23. Altogether, this implicates TNF-α in impaired 
wound healing in T2DM.
TNF-α also stimulates the secretion of proteolytic enzymes such as matrix metalloproteases (MMPs), specifi-
cally MMP-1,-2,-3,-9 and -13; elevated levels of which have been associated with chronic  wounds24–26. In normal 
human skin, MMP expression is low and is controlled by tissue inhibitors of MMPs (TIMPs). However, during 
wound repair MMP secretion is stimulated by pro-inflammatory cytokines, which also down-regulate TIMP 
 synthesis27,28. MMP secretion is required for wound repair because they have a key role in the degradation and 
remodelling of the ECM, in addition to facilitating the migration of keratinocytes and fibroblasts. However, fail-
ure to control their expression due to persistent, chronic inflammation, can lead to disproportionate proteolytic 
activity and excessive ECM degradation, resulting in an impaired healing  response28. DF within these wounds 
are unable to proliferate and/or migrate since their functional receptors that respond to cytokines and growth 
factors have been down-regulated26,28,29.
While the role of DF in ECM assembly has long been recognised, additional roles during cutaneous wound 
healing are starting to emerge. Although inflammatory cells are the main source of TNF-α, it is also secreted 
by other by cells including  DF24,30. Since DF have a central role in regulating acute and chronic inflammation, 
fibrosis, and the resolution of inflammation, they may act as a gatekeeper of the inflammatory response in human 
skin during wound healing.
In this study we sought to clarify whether there were phenotypic differences in primary DF cultures from 
the skin of donors with T2DM (T2DM-DF) and no diagnosis of diabetes (ND-DF), which may impact on their 
responses in a wound healing environment. Furthermore, their responses to TNF-α, which is prevalent in chronic 
wounds, was also assessed. While the basal secretion of TNF-α levels by T2DM-DF and ND-DF was similar, we 
discovered that T2DM-DF were resistant to the anti-proliferative, pro-quiescent and pro-inflammatory effects 
of TNF-α. By contrast, the anti-migratory stimulus of TNF-α was retained. Understanding the disparity in the 
function of T2DM-DF may help to identify markers for new therapeutic targets to improve the treatment of 
chronic, non-healing wounds and diabetic foot ulcers.
Results
Levels of TNF‑α secreted by dermal fibroblasts in vitro are not affected by diabetes. To estab-
lish whether there were any basal differences in the phenotype of ND-DF and T2DM-DF, we monitored their 
proliferation, migration and secretion of TNF-α under standard cell culture conditions. ND-DF increased in 
cell number by 1.7-fold in response to 10% FBS over 7 days. This was paralleled by an increase of 2.7-fold in 
T2DM-DF (ND-DF n = 3, T2DM-DF n = 3; Fig. 1a). Similarly, the migration rates of ND-DF and T2DM-DF 
over 24  h were comparable (350  μm vs 438  μm respectively; both n = 4; Fig.  1b). Furthermore, under non-
stimulated conditions, ND-DF secreted 89.2 ± 6.8 pg/ml TNF-α, whereas T2DM-DF secreted 101.6 ± 5.9 pg/ml 
TNF-α (both n = 4, P = 0.8426, two-way ANOVA). As expected, in both populations there was significantly more 
TNF-α present in the conditioned medium (CM) following TNF-α treatment (P = 0.0023 for effect of TNF-α, 
two-way ANOVA), but this increase was the same regardless of diabetes status (371.5 ± 63.6 vs 384.2 ± 97.3 pg/
ml respectively; two-way ANOVA, n = 4; Fig. 1c). Altogether, this demonstrates that the phenotype of DF under 
control conditions is not affected by T2DM, and that TNF-α secretion under basal and stimulated conditions 
is comparable between ND and T2DM-DF. However, we were interested in how the cells reacted to the pro-
inflammatory stimulus of TNF-α to interrogate how wound healing is impacted in the hyper-inflammatory 
condition of T2DM.
T2DM‑DF are resistant to the anti‑proliferative effects of TNF‑α. Prior exposure to 2.5  ng/ml 
TNF-α for 3 days significantly inhibited ND-DF proliferation at 4 and 11-days post-TNF-α withdrawal by 41.3% 
and 69.1% respectively, despite the presence of 10% FBS (P = 0.0142 for effect of TNF-α, two-way ANOVA, 
n = 4). The higher concentration of 25 ng/ml TNF-α also significantly inhibited ND-DF proliferation but this was 
blunted and only significant at day 14 (by 43.7%; Fig. 1d), suggesting that 2.5 ng/ml was a maximal stimulus for 
proliferation. In contrast, TNF-α did not have any impact on T2DM-DF at either concentrations or time points 
tested (n = 4, Fig. 1e). The reduction in proliferation in ND-DF was not due to an increase in apoptosis as TNF-α 
had no impact on cell viability (n = 2).
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Figure 1.  TNF-α has a differential effect on ND-DF and T2DM-DF proliferation. DF were quiesced for 24 h 
and then treated with DMEM + 10% FBS. (a) Basal proliferation rates were quantified by cell counting at days 2, 
3 and 7 (n = 3 donors ND-DF, n = 4 donors T2DM-DF). (b) Basal migration rates were quantified using scratch 
wound assay (both n = 4 donors). (c) Confluent cells were quiesced for 24 h before being stimulated ± 2.5 ng/ml 
TNF-α for 24 h. Supernatants were collected and the concentration of TNF-α quantified (both n = 4 donors). (d) 
Cells were quiesced for 24 h and treated with 2.5 and 25 ng/ml TNF-α for 72 h before being transferred into full 
growth medium in the absence of TNF-α. Fluorescence was measured on days 0, 3, 7 and 14 and the percentage 
inhibition from control calculated for ND-DF and (e) T2DM-DF (both n = 4 donors). (f–g) Parallel cultures 
were fixed and stained for senescence-associated β-galactosidase in ND-DF and T2DM-DF at day 3 and (h–i) 
day 7 (both n = 4 donors). Blue arrowheads indicate senescent cells and white arrowheads indicate unstained 
cells. Two-way ANOVA with Sidak post-hoc test *P < 0.05, ***P < 0.001, ns = non-significant.
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TNF‑α does not induce dermal fibroblast senescence. We measured senescence-associated 
β-galacotosidase to investigate whether the reduced cell number in TNF-α-treated ND-DF primary cell cul-
tures was due to induction of senescence. Three days after withdrawal of TNF-α, there was no significant differ-
ence between the senescence rates of ND-DF and T2DM-DF (1.78 ± 0.8 vs 0.69 ± 0.2 A.U., P = 0.1832, two-way 
ANOVA, n = 4). TNF-α concentration had no impact on senescence in either ND-DF or T2DM-DF (P = 0.1556, 
two-way ANOVA, both n = 4). At day 7, senescence scores for all DF were slightly elevated from day 3 levels 
but again there was no significant difference between ND-DF and T2DM-DF (3.20 ± 1.16 vs 2.21 ± 0.85 A.U., 
P = 0.5718, two-way ANOVA, n = 4), and TNF-α had no impact under any conditions (P = 0.5196, two-way 
ANOVA, both n = 4). Senescence-associated β-galacotosidase analysis at day 14 was not performed, as the cells 
had grown too confluent for individual cells to be visualised.
TNF‑α induces transient changes in ND‑DF morphology. The morphological characteristics of the 
cells in the senescence assay were measured to assess whether TNF-α exposure was influencing fibroblast pheno-
type in vitro. Reductions in cell size indicate quiescence, whereas changes in circularity/cell projections can rep-
resent DF  activation31,32 Three days after withdrawal of TNF-α, there was a significant, concentration-dependent 
decrease in spread cell area in ND-DF (32.1% reduction in cell area with 2.5 ng/ml, 50.4% reduction with 25 ng/
ml TNF-α; P = 0.012 for effect of TNF-α, two-way ANOVA n = 4). However, there was no change in circularity 
suggesting that the cells were simply becoming smaller in size rather than more spindle shaped. In contrast, 
TNF-α had no impact on T2DM-DF morphology (Fig. 2a,c,e, n = 4). By day 7, the TNF-α-induced reduction in 
ND-DF spread cell area was lost (Fig. 2b,d,f, n = 4).
TNF‑α inhibits migration in both ND‑DF and T2DM‑DF. As wound healing and tissue regeneration 
requires both cell proliferation and migration to act in concert, we also evaluated the impact of TNF-α on cell 
migration using the scratch-wound assay. TNF-α significantly inhibited migration by ~ 25% at both 2.5 and 
25 ng/ml, and in both ND-DF and T2DM-DF (P = 0.0008 for effect of TNF-α, two-way ANOVA, both n = 4; 
Fig. 3a-c).
MMP‑9 is selectively upregulated by TNF‑α in ND‑DF and T2DM‑DF. The gelatinases MMP-2 and 
MMP-9 both facilitate fibroblast migration during the wound healing response. MMP2 gene expression was 
unaffected by either concentration of TNF-α, or the presence of diabetes (ND-DF n = 5, T2DM-DF n = 4, Fig. 4a) 
and this was mirrored at the protein level (n = 4, Fig. 4b-c). In contrast MMP9 gene expression was significantly 
increased by TNF-α at both 2.5 and 25  ng/ml, and in both ND-DF and T2DM-DF to a comparable degree 
(P < 0.0001 for effect of TNF-α, two-way ANOVA, n = 5 ND-DF and n = 4 T2DM-DF; Fig. 4d). MMP-9 protein 
was only detected by zymography in one ND-DF line (where it increased in a TNF-α concentration-dependent 
manner), yet it was readily detected in 3 out of the 4 T2DM-DF, where there was a suggestion that it may increase 
in a TNF-α concentration dependent manner, though this was not statistically significant (Fig. 4e-f).
Neither TIMP1 nor TIMP2 gene expression was affected by either concentration of TNF-α, however T2DM-
DF had a 1.7-fold higher basal expression of TIMP2 than ND-DF (579.8 ± 42.9 vs 340.4 ± 54.8% GAPDH respec-
tively; ND-DF n = 5, T2DM-DF n = 4, Fig. 4g-h), although this did not reach statistical significance.
TNF‑α induces the expression of the pro‑inflammatory cytokines CCL2, CXCL1 and SERPINE1 
in DF in vitro. T2DM is a hyper-inflammatory condition that impacts on wound healing. Therefore, we 
sought to assess whether there were any basal differences in the pro-inflammatory cytokine expression profile 
between ND-DF and T2DM-DF, and whether TNF-α stimulation altered this profile. The Cytokine Profiler 
Array indicated that 9 pro-inflammatory cytokines were secreted by ND-DF and T2DM-DF (Fig. 5a-e). From 
these, we chose 4 candidates to validate using RT-PCR, to quantitate differences in their level of production. 
These were C–C motif ligand 2 (CCL2, also known as monocyte chemoattractant protein 1, MCP-1), C-X-C 
motif chemokine ligand (CXCL1, also known as fibroblast secretory protein, FSP), macrophage migration inhib-
itory factor (MIF) and SERPINE1 (also known as plasminogen activator inhibitor 1, PAI-1).
Basal CCL2 expression was higher in T2DM-DF (78.7 ± 75.3 vs 0.8 ± 0.4% GAPDH, n = 4), however this was 
skewed by one T2DM-DF population with an exceptionally high expression level (P = 0.0733, two-way ANOVA, 
n = 4). TNF-α induced CCL2 expression in ND-DF by 32-fold over basal unstimulated levels (Fig. 5f, n = 4). 
CXCL1 expression followed a similar pattern, whereby basal expression level was higher in T2DM-DF (skewed 
by the same T2DM-DF population; P = 0.2870, two-way ANOVA, n = 4) and was significantly induced by TNF-α 
in ND-DF only, by 27-fold (Fig. 5g, n = 4).
In contrast, MIF expression was significantly reduced in T2DM-DF compared to ND-DF (58.7 ± 12.3 vs 
280.4 ± 126.2% GAPDH; P = 0.0016 for effect of diabetes, two-way ANOVA, n = 4), while TNF-α had no modula-
tory effect in either (P = 0.7303 for effect of TNF-α, two-way ANOVA, n = 4; Fig. 5h). SERPINE1 expression was 
significantly higher in T2DM-DF (53.03 ± 19.1 vs. 1.42 ± 1.19% GAPDH; P = 0.0072 for effect of T2DM, two-way 
ANOVA, n = 4). Whilst TNF-α induced a significant 2.6-fold increase in SERPINE1 mRNA in ND-DF, there was 
no effect of TNF-α in T2DM-DF (P = 0.0035 for effect of TNF-α, two-way ANOVA, n = 4; Fig. 5i).
Discussion
During the early phase of wound repair, there is increasing evidence that DF are a primary source of TNF-α33. 
While there have been no previous studies comparing TNF-α secretion in DF from patients with or without 
diabetes, we hypothesised that there may be significant differences in the secretion and/or response to TNF-α by 
DF derived from T2DM skin that may impact on wound healing. We initially compared the basal proliferation, 
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migration and secretion of TNF-α by primary cultures of ND-DF and T2DM-DF (Figs. 1a-c) and found no 
significant difference. Furthermore, although pre-incubation with TNF-α significantly upregulated its secre-
tion, there was no difference between the two cell types (Fig. 1c), demonstrating any differences observed in 
response to TNF-α (e.g. proliferation, migration, secretion of cytokines) are not due to underlying differences 
in the amount of TNF-α the cells may produce.
Therefore, we sought to determine whether their responses to exogenous TNF-α differ. In normal wound 
healing TNF-α levels increase approximately 12 to 24 h after wounding, returning to basal levels following the 
proliferative  phase24, so we exposed cultured ND-DF and T2DM-DF to supra-physiological doses of TNF-α for 
3 days, before removing and culturing in the absence of TNF-α for a further 11 days (14 days in total) to mimic 
this transiency. While TNF-α had no direct effect on cell number at day 3, prior exposure significantly inhibited 
Figure 2.  TNF-α has a differential effect on ND-DF and T2DM-DF morphology. The morphology of DF 
in images taken from the senescence assay were analysed using Image J. (a) Mean spread cell area and (b) 
circularity of ND- and T2DM-DF at day 3 post-TNF-α withdrawal (both n = 4 donors). (c) Representative 
images. (d) Mean spread cell area and (e) circularity of ND-DF and T2DM-DF at day 7 post-TNF-α withdrawal 
(both n = 4 donors). (f) Representative images. Two-way ANOVA with Sidak post-hoc test *P  < 0.05, ***P 
< 0.001, ns = non-significant. 
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Figure 3.  Migratory capacity of ND-DF and T2DM-DF. (a) Confluent cells were quiesced for 24 h before 
being scratched, stimulated ± 0–25 ng/ml TNF-α and imaged. Repeat images were taken of the same wounds 
24 h later. The percentage inhibition of TNF-α on migration was calculated by dividing the distance migrated in 
control cells by the distance migrated in treated cells (both n = 4 donors). (b) ND-DF representative images, (c) 
T2DM-DF representative images. Two-way ANOVA with Sidak post-hoc test, *P < 0.05, ns = non-significant.
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ND-DF proliferation (Fig. 1d) but did not reduce T2DM-DF proliferation (Fig. 1e) by day 14. In vivo, human 
DF are not rapidly dividing cells; their primary function is to maintain the homeostasis of the dermis by col-
lagen synthesis and modelling of the  ECM34. Therefore, following the proliferative phase of wound repair, DF 
proliferation abates to enter the remodelling phase. Our data suggest T2DM-DF have lost the normal response 
to the resolution of the inflammatory phase and subsequent reduction in circulating TNF-α which may likely 
impair the synthesis and remodelling of the ECM.
Since sub-lethal doses of pro-inflammatory cytokines induce senescence, we next measured expression of 
senescence-associated β-galactosidase following pre-incubation with TNF-α. However, this did not induce 
senescence in either ND-DF or T2DM-DF, indicating that reduced cell number in ND-DF was not due to per-
manent withdrawal from the cell cycle (Fig. 1f-i). Reduction in cell number can be indicative of transient cell 
cycle withdrawal – quiescence – and so we compared the effect of TNF-α on cell morphology. Three days after 
TNF-α withdrawal there was a significant decrease in spread cell area in ND-DF (Fig. 2a), returning to control 
Figure 4.  Matrix remodelling in ND-DF and T2DM-DF. (a) Cells used in the migration assay were collected 
and total RNA extracted. MMP2 gene expression was quantified and expressed relative to GAPDH (both n = 4 
donors). (b) Conditioned media from the migration assays was analysed for MMP-2 secretion using gelatin 
zymography (both n = 4 donors), (c) representative images. (d) MMP9 gene expression and (e–f) protease 
activity were analysed using the same method (both n = 4 donors). (g) TIMP1 and (h) TIMP2 gene activity in 
the same cells (both n = 4 donors). Two-way ANOVA with Sidak post-hoc test ***P < 0.001, ns = non-significant.
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Figure 5.  Cytokine secretion in ND-DF and T2DM-DF. The secretion of multiple cytokines was measured 
in conditioned media from the migration assays using R&D Systems Human Cytokine Array Panel A. (a) 
Heatmap of the cytokines contained within the array and expression in ND and T2DM-DF, both basally and in 
response to 2.5 ng/ml TNF-α. (b) Representative dot blot used in the heatmap analysis for ND-DF under control 
(basal conditions), (c) ND-DF in response to TNF-α, (d) T2DM-DF under control (basal conditions) and (e) 
T2DM-DF in response to TNF-α. (f) Gene expression of CCL2, (g) CXCL1, (h) MIF and (i) SERPINE1 was 
measured in the cells from the migration assays (both n = 4 donors). Two-way ANOVA with Sidak post-hoc test, 
**P < 0.01, *P < 0.05, ns = non-significant.
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levels at day 7. In contrast, TNF-α did not impact T2DM-DF morphology. Collectively, this suggests rather than 
senescence, TNF-α induces quiescence, by which normal fibroblasts halt proliferation but remain metabolically 
healthy. While quiescent fibroblasts have reduced size, and are non-proliferating, they have a high metabolic 
 activity31. A recent study has reported that when human mesenchymal stem cells quiesce in response to environ-
mental challenges, they have a higher tolerance to stress than proliferating cells, important for ensuring tissue 
 maintenance35. The high metabolic activity reported by quiescent fibroblasts is likely due to ECM synthesis, since 
contact-inhibited fibroblasts secrete more fibronectin, collagen, and laminin than proliferating  fibroblasts31. In 
the present study, the shift in ND-DF phenotype (Fig. 2a) may be particularly significant during wound repair, 
because subsequent to the inflammatory phase, quiescent, non-proliferating fibroblasts are essential for ECM 
synthesis and tissue homeostasis. It is noteworthy that this was not observed in T2DM-DF, suggesting their 
normal physiological responses have been lost and may explain the impaired production of granulation tissue 
in diabetic patients that can result in a non-healing wound.
Fibroblast migration is also key to wound repair. A previous study reported that TGF-α stimulated migration 
of cultured human DF is inhibited by 20 ng/ml TNF-α by suppressing trans-differentiation into  myofibroblasts36. 
In mice, diabetic DF have an impaired migratory ability, migrating 75% less than the normal  DF37. In contrast 
to the differential proliferative and quiescent effects (Figs. 1, 2) observed, there was a significant inhibition of 
ND-DF and T2DM-DF migration in response to TNF-α (Fig. 3), where both responded in a similar manner.
A pro-inflammatory environment can increase MMP expression which has been implicated in impaired 
wound healing in both T2DM and animal models of diabetic  skin24,38,39. Furthermore, in a pro-inflammatory 
environment, increased activity of MMPs has been shown to impair dermal fibroblast  migration15,20,40. Therefore, 
we sought to establish whether there was a difference in expression and activity of MMPs and TIMPS between 
ND-DF and T2DM-DF, or their responses to TNF-α. We observed no difference in MMP-2 expression at either 
gene or protein level, regardless of diabetic status or the presence of TNF-α (Fig. 4a-c). However, MMP-9 mRNA 
expression was induced to a similar degree by TNF-α in both cell types (Fig. 4d). Most studies indicate that nor-
mal human DF do not express MMP-9, and in keeping with this, protein expression of MMP-9 was detected in 
only one of the four ND-DF donors, but in three of the four T2DM-DF (Fig. 4e). Chronic diabetic wounds have 
been reported to have an imbalance of MMP:TIMP ratios, skewed in favour of increased  MMPs9,41. Indeed, the 
MMP-9/TIMP-1 ratio in wound fluids correlates with the probability of ulcer healing, highlighting the detri-
mental effect of MMP-9 in chronic  wounds42. In the present study, expression of both TIMP1 and TIMP2 were 
unaffected by TNF-α (Fig. 4g-h), although interestingly T2DM-DF had a higher basal level of TIMP2 mRNA 
than ND-DF (Fig. 4h).
In addition to ECM modulators (MMPs and TIMPs), DF also secrete pro-inflammatory cytokines, so we 
sought to identify differences between ND-DF and T2DM-DF in their secretion of other pro-inflammatory 
cytokines, and if these were modulated by TNF-α (Fig. 5a-e). A number were secreted by both ND-DF and 
T2DM-DF, including CCL2, CXCL1, MIF, SERPINE1/PAI-1, chemokine C-X-C motif ligand 12/ stromal cell-
derived factor 1 (CXCL12/SDF-1), interleukin-6 (IL-6) and interleukin-8 (IL-8). Full-skin substitutes and auto-
graft studies have shown DF and keratinocytes secrete IL-6, IL-8, CCL2 and CXCL1, important mediators of 
wound  healing30. IL-6 is increased in both human and animal chronic  wounds43–46 and induced in DF by TNF- 
α47. Our observation that both IL-6 and IL-8 were upregulated by TNF-α (Fig. 5a) concurs with this, confirming 
DF respond to TNF-α in culture by increasing secretion of pro-inflammatory cytokines.
The expression of CCL2, CXCL1, MIF and SERPINE1/PAI-1 were further validated by qRT-PCR (Fig. 5f-i). 
DF secrete CCL2 to accelerate leukocyte homing and promote endothelial activation in  inflammation48. Likewise, 
CXCL1 promotes neutrophil infiltration. In the present study, expression of CCL2 and CXCL1 was highly variable 
in T2DM-DF with neither modulated by TNF-α, while in contrast TNF-α increased expression of both CCL2 and 
CXCL1 in ND-DF (Fig. 5f-g). Reduced sensitivity to TNF-α by T2DM-DF may reflect their higher basal expres-
sion of these cytokines. MIF has a role in the insulin biosynthesis  pathway49, although its exact role in wound 
healing is still a matter of  debate50,51. Similarly, fluctuations in MIF concentrations in chronic venous ulcers lack 
 consensus52,53. In the current study, TNF-α had no effect on MIF expression in either cell type, but expression 
was significantly lower in T2DM-DF (Fig. 5h). One function of MIF is to stimulate the chemotactic migration 
of endothelial progenitor cells (EPCs) and promote  revascularisation53. Therefore, reduced expression of MIF 
in T2DM-DF may be one factor in impaired angiogenesis in diabetic wounds. SERPINE1 has pro-inflammatory 
effects including macrophage activation, and a well-described role in  fibrosis54. TNF-α is a strong agonist for 
SERPINE1 expression and may contribute to elevated plasma levels in obesity, indeed high levels are considered 
to be biomarkers for  T2DM55. We observed significantly higher SERPINE1 expression in T2DM-DF, and whilst 
TNF-α significantly increased expression in ND-DF, it did not modulate expression in T2DM-DF (Fig. 5i), again 
suggesting T2DM-DF have lost their normal responses to TNF-α. The significantly higher levels expressed by 
T2DM-DF may contribute to dysregulated maintenance of the provisional fibrin matrix by inhibiting fibrinolysis 
in the early stages of wound healing, thus impeding the resolution of inflammation.
The persistence of hyperglycemia-associated epigenetic patterns sustains and drives progression of disease 
phenotypes, despite removal of the glycemic  environment56. The role of epigenetic metabolic memory in estab-
lishing a diabetic phenotype has been demonstrated in a number of cell types, including DF derived from chronic, 
non-healing diabetic foot  ulcers57 and smooth muscle cells from T2DM  patients58. Our data highlight significant 
differences between T2DM-DF and ND-DF supporting the view that epigenetic-related metabolic memory in 
human DF may be the basis for the divergence in phenotypes associated with poor wound healing outcomes in 
T2DM patients. DF are important mediators of crosstalk between multiple cell types vital for normal wound 
healing, therefore, understanding their role in both the initiation and maintenance of the diabetic non-healing 
wound environment is paramount in the drive to identify new therapeutic targets for the treatment of chronic, 
non-healing diabetic foot ulcers.
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Methods
Dermal fibroblast isolation. DF were isolated from human skin provided by Ethical Tissue, University of 
Bradford. The use of human skin for this project was granted by the Yorkshire & the Humber—Leeds East Ethics 
Committee (reference numbers 17/YH/0086 and 07/H1306/98 + 5) and all donors gave informed consent. All 
methods were performed in accordance to the relevant guidelines and regulations. DF were isolated using an 
explant technique as previously  described59. Briefly underlying fat was removed, before cutting skin into 1  cm2 
pieces, washing in phosphate buffer saline (PBS) containing penicillin/streptomycin (100U/ml/100 μg/ml) and 
amphotericin B (250 μl/ml), and digesting overnight at 4C in 0.1% dispase in PBS. The epidermis was removed 
and pieces of dermis washed in growth media (Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented 
with 10% foetal bovine serum (FBS) l-glutamine (10 mM) and penicillin, streptomycin and amphotericin B 
(100 U/ml, 100 μg/ml, 250 μl/ml respectively), before transferring to a T75 tissue culture flask containing fresh 
media and incubating at 37 °C in 5%  CO2 to allow DF explant, which took 5–10 days. Once confluent cells were 
serially passaged at a ratio of 1:3. Patients without diabetes (ND) demographics were 100% female, age range 
36–67  years. Patients with diabetes (T2DM) were 50% female, age range 52–66  years. All experiments were 
performed on cells at passage 3–6.
ELISA. DF were quiesced for 24 h and then treated with TNF-α (0–2.5 ng/ml) in DMEM + 10% FBS for 24 h. 
Conditioned medium was collected and the concentration of TNF-α quantified using a Human TNF-α Quan-
tikine ELISA (R&D Systems) according to manufacturer’s instructions.
Proliferation. Basal DF proliferation rates were assessed by cell counting. DF were plated in triplicate at 
a density of 20,000 cells per well in 24-well plates. Cells were quiesced in DMEM containing 0% serum (SF 
medium) for 24 h and then treated with DMEM + 10% FBS for up to 7 days. Viable and non-viable cells were 
counted using trypan blue and a haemocytometer, and media replenished, on days 0, 3, 5 and 7.
To assess the impact of TNF-α on proliferation, DF were seeded in 96-well plates in quadruplicate at a 
density of 2,000 cells per well, quiesced in SF DMEM for 24 h and then treated with TNF-α (0–250 ng/ml) in 
DMEM + 10% FBS for 72 h. Medium was removed and replaced with DMEM + 10% FBS only for up to 14 days, 
and replenished every 3 days. DF proliferation was quantified using the CyQUANT fluorescence-based assay 
according to manufacturers’ instructions (Invitrogen). Fluorescence was measured at excitation 508 nm and 
emission 527 nm. Cell number was interpolated from a standard curve of 1–5000 cells at days 3, 7 and 14.
Senescence. DF were seeded in 6-well plates at a density of 7000 cells per well and treated as described for 
the proliferation assay. At days 3, 7 and 14, cells were fixed, and senescence approximated using the senescence-
associated β-galactosidase kit (Cell Signaling Technology) according to manufacturers’ instructions. After stain-
ing, 5 random fields of view (× 100 magnification) were captured from each treatment well for each patient, and 
a senescence score calculated from the ratio of positively stained senescent cells (blue) and the total number of 
cells present in the field as previously  described60.
Morphological measurements. Morphological characteristics of the cells were captured from the images 
generated from the senescence staining. Fifty random cells per patient per treatment were traced using Image J, 
and the spread cell area and circularity  quantified58.
Scratch wound migration. Confluent DF were quiesced in SF medium for 24 h. A 0.8 mm wide linear 
scratch was made in triplicate monolayers and dislodged cells removed by washing in  PBS61. DF were incubated 
in DMEM + 10% FBS with 0–25 ng/ml TNF-α for 24 h. Images were captured at × 40 magnification at 0 and 24 h. 
The migration distance between the wound edges was measured at 6 identical points in triplicate wells and the 
average taken. For TNF-α experiments, data is expressed as the percentage inhibition of migration compared to 
control (0 ng/ml) wells.
Gene expression. Following 24 h imaging of the migration assays, total RNA was extracted from DF using 
RNeasy mini kit (Qiagen) and reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) according to manufacturers’ instructions. Gene expression of CCL2, CXCL1, GAPDH, 
MIF, MMP2, MMP9, TIMP1, TIMP2, and SERPINE1 was measured in triplicate using specific TaqMan assays 
and expressed as a proportion of GAPDH using the formula  2−ΔCt.
Gelatin zymography. Confluent DF were quiesced in SF medium for 24 h and treated with 2.5–25 ng/ml 
TNF-α for 48 h. Conditioned medium was collected, centrifuged at 600 g for 6 min to remove cell debris and 
snap frozen until needed for zymographical analysis. Conditioned medium was diluted (1:40) with non-reduc-
ing sample buffer and electrophoresed in an 10% SDS-gel containing 1.5 mg/ml gelatin for 110 min at 120 V. SDS 
was removed by washing in 2.5% Triton X-100 solution for 1 h and the gels placed in incubation buffer (50 mM 
Tris–HCl, 10 mM  CaCl2, 0.05% Brij, pH7.4) for 18 h (MMP-2 activity) or 24 h (MMP-9). Gels were stained with 
0.1% Coomassie blue for 20 min and gelatinase activity visualised as clear bands of lysis on a dark background. 
MMP-2 and MMP-9 were measured using densitometry (Image J) and normalised to control (0 ng/ml)  values62. 
Conditioned media from ND-DF treated with 100 nM phorbol 12-myristate 13-acetate (PMA) for 24 h was used 
as a marker for MMP-2 and MMP-9.
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Cytokine profiler array. Conditioned medium collected from the migration assays was used to evalu-
ate a number of inflammatory cytokines using the Human Cytokine Array Panel A (R&D Biosystems) as per 
manufacturers’ instructions. The conditioned medium was centrifuged to remove any cellular debris and 1 ml 
was diluted with 0.5 ml of assay buffer (see https ://www.rndsy stems .com/produ cts/prote ome-profi ler-human 
-cytok ine-array -kit_ary00 5b for full methodology). Following completion, integrated density of the dots was 
calculated. Briefly, the mean densitometry of duplicate dots was measured using Image J. The reciprocal was 
calculated which was then corrected for the value of the background densitometry. Then, the integrated density 
of each pair of cytokines was expressed as a proportion of the integrated density of the reference spots that were 
included on all membranes. Expression was stratified into low (< 0.1 A.U.), medium (0.1–2 A.U.) or high (> 2 
A.U.).
Statistical analysis. Data are presented as mean ± standard error. Normalised data was transformed using 
the formula Y = log[Y]. n refers to the number of patient donors used in each experiment. All data was analysed 
using two-way ANOVA with Sidak post-hoc test. Alpha = 0.05 and P < 0.05 was considered statistically signifi-
cant.
Data availability
All data are available upon request.
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